癌症中线粒体研究进展述评。
A Review of Advances in Mitochondrial Research in Cancer.
机构信息
Graduate School, North China University of Science and Technology, Tangshan, China.
The Fourth Department of Oncology, Hebei General Hospital, Shijiazhuang, China.
出版信息
Cancer Control. 2024 Jan-Dec;31:10732748241299072. doi: 10.1177/10732748241299072.
BACKGROUND
Abnormalities in mitochondrial structure or function are closely related to the development of malignant tumors. Mitochondrial metabolic reprogramming provides precursor substances and energy for the vital activities of tumor cells, so that cancer cells can rapidly adapt to the unfavorable environment of hypoxia and nutrient deficiency. Mitochondria can enable tumor cells to gain the ability to proliferate, escape immune responses, and develop drug resistance by altering constitutive junctions, oxidative phosphorylation, oxidative stress, and mitochondrial subcellular relocalization. This greatly reduces the rate of effective clinical control of tumors.
PURPOSE
Explore the major role of mitochondria in cancer, as well as targeted mitochondrial therapies and mitochondria-associated markers.
CONCLUSIONS
This review provides a comprehensive analysis of the various aspects of mitochondrial aberrations and addresses drugs that target mitochondrial therapy, providing a basis for clinical mitochondria-targeted anti-tumor therapy.
背景
线粒体结构或功能异常与恶性肿瘤的发展密切相关。线粒体代谢重编程为肿瘤细胞的生命活动提供了前体物质和能量，使癌细胞能够快速适应缺氧和营养缺乏等不利环境。线粒体可以通过改变组成型连接、氧化磷酸化、氧化应激和线粒体亚细胞再定位，使肿瘤细胞获得增殖、逃避免疫反应和发展耐药性的能力。这极大地降低了肿瘤有效临床控制的速度。
目的
探讨线粒体在癌症中的主要作用以及靶向线粒体治疗和与线粒体相关的标志物。
结论
本综述对线粒体异常的各个方面进行了全面分析，并讨论了靶向线粒体治疗的药物，为临床线粒体靶向抗肿瘤治疗提供了依据。
Zotero 插件